Dekkers et al. (2013) found that the function of the CFTR F508del mutant protein was restored by CFTR-restoring compounds. Wong et al. (2022) revealed the conductance defect of the rare CFTR mutation R352Q. Organoids derived from CF patients are also used to generate biobank for the study of gene correction by adenine base editors and CFTR repair (Geurts et al., 2020). CFTR is an attractive target for gene editing approaches. Gene therapy has been used to correct the CFTR locus using CRISPR/Cas9 and homologous recombination in CF patient-derived organoids. Here, CFTR is linked to cystic fibrosis.